Golocdacimab Reference: HY-P99646 Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes.
Avelumab Reference: HY-108730 Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Navicixizumab Reference: HY-P99377 Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
Sarilumab Reference: HY-P9916 Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis.
KWAR 23 Reference: HY-P99175 KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
Mirococept Reference: HY-P99738 Mirococept (APT070) is an antibody targeting to complement system C3b/C4b, as well as a membrane-localizing C3 convertase inhibitor. Mirococept reduces the release of C-peptide and pro-inflammatory cytokines, and reduces the infiltration of inflammatory cells. Mirococept reduces intraislet inflammation, which is beneficial to islet transplantation. Mirococept also inhibits increased intestinal and pulmonary vascular permeability to reduce neutrophil influx.
Enokizumab Reference: HY-P99193 Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways.
Omodenbamab Reference: HY-P99770 Omodenbamab is an anti-SpA (Staphylococcal protein A) humanized monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection.
Robatumumab Reference: HY-P99218 Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
Lulizumab pegol Reference: HY-P99717 Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease.
Obexelimab Reference: HY-P99761 Obexelimab (XmAb5871) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab can be used in research of autoimmune.
Felvizumab Reference: HY-P99615 Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV.